Nisa Investment Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-345
Closed -$6.4K 2807
2023
Q3
$6.4K Hold
345
﹤0.01% 2258
2023
Q2
$3.82K Sell
345
-22
-6% -$307 ﹤0.01% 2337
2023
Q1
$5K Hold
367
﹤0.01% 2250
2022
Q4
$5K Buy
367
+22
+6% +$312 ﹤0.01% 2302
2022
Q3
$5K Hold
345
﹤0.01% 2307
2022
Q2
$5K Hold
345
﹤0.01% 2278
2022
Q1
$6K Hold
345
﹤0.01% 2301
2021
Q4
$6K Sell
345
-3,700
-91% -$62.4K ﹤0.01% 2086
2021
Q3
$60 Hold
4,045
﹤0.01% 1896
2021
Q2
$81 Buy
4,045
+3,700
+1,072% +$73.4K ﹤0.01% 1797
2021
Q1
$8 Hold
345
﹤0.01% 2235
2020
Q4
$9K Sell
345
-850
-71% -$28.2K ﹤0.01% 2226
2020
Q3
$50K Buy
1,195
+1,000
+513% +$45.9K ﹤0.01% 1813
2020
Q2
$9K Buy
195
+15
+8% +$1.16K ﹤0.01% 1951
2020
Q1
$11K Sell
180
-120
-40% -$10.8K ﹤0.01% 1843
2019
Q4
$37K Buy
300
+200
+200% +$17.9K ﹤0.01% 1584
2019
Q3
$7K Hold
100
﹤0.01% 1857
2019
Q2
$8K Hold
100
﹤0.01% 1821
2019
Q1
$11K Hold
100
﹤0.01% 1732
2018
Q4
$10K Hold
100
﹤0.01% 1663
2018
Q3
$13K Buy
+100
New +$10.6K ﹤0.01% 1657

Nisa Investment Advisors's ICPT Position: Q4 2023 in Review

Nisa Investment Advisors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 345 shares — an estimated $6.4K sold.

Nisa Investment Advisors first reported a position in ICPT in Q3 2018 and held it in 21 quarters. The position peaked at $50K in Q3 2020. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.

  • Nisa Investment Advisors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
  • Nisa Investment Advisors sold 345 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $6.4K.
  • Nisa Investment Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2018 and held it in 21 quarters.
  • Nisa Investment Advisors's Intercept Pharmaceuticals, Inc. position peaked at $50K in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.

Based on Nisa Investment Advisors's 13F filing for Q4 2023, filed 25 Jan 2024.